GlassScriptPhysician profile
Nabila Elzind
NPI 1003849035
$16,384.82
in general payments reported to CMS, 2019-2025
55 companies · $2,645 in 2025
The $2,645 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,904 · 2020: $2,333 · 2021: $2,629 · 2022: $2,026 · 2023: $2,344 · 2024: $2,504 · 2025: $2,645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,276 · Education: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,275.83 |
| Education | $217.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,118.03 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Emd Serono, INC. | $1,704.24 | 2019-2025 | Mavenclad |
| Biogen, INC. | $1,433.38 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Novartis Pharmaceuticals Corporation | $1,155.04 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $803.04 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Eisai INC. | $679.96 | 2019-2025 | |
| Genentech USA, INC. | $674.46 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Supernus Pharmaceuticals, INC. | $641.13 | 2019-2025 | Qelbree |
| Amgen INC. | $593.22 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $573.89 | 2024-2025 | Purified Cortrophin Gel |
| Acadia Pharmaceuticals INC | $565.22 | 2019-2024 | Nuplazid |
| Neurocrine Biosciences, INC. | $505.41 | 2019-2025 | Ingrezza |
| Kyowa Kirin, INC. | $494.58 | 2020-2024 | Nourianz |
| Genzyme Corporation | $451.02 | 2019-2022 | |
| Sk Life Science, INC. | $435.34 | 2020-2025 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nabila Elzind listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.